GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Interest and Commission Paid

Scancell Holdings (LSE:SCLP) Interest and Commission Paid


View and export this data going back to 2010. Start your Free Trial

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Scancell Holdings (LSE:SCLP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.